JAZZ (Jazz Pharmaceuticals, Inc.) Stock Analysis - News
Jazz Pharmaceuticals, Inc. (JAZZ) is a publicly traded Healthcare sector company. As of May 21, 2026, JAZZ trades at $242.70 with a market cap of $14.40B and a P/E ratio of 26.45. JAZZ moved +0.70% today. Year to date, JAZZ is +37.05%; over the trailing twelve months it is +115.29%. Its 52-week range spans $95.49 to $242.18. Analyst consensus is strong buy with an average price target of $241.43. Rallies surfaces JAZZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in JAZZ news today?
Jazz Pharmaceuticals jumps on Q1 revenue surge, EPS beat, and reaffirmed 2026 outlook: Jazz Pharmaceuticals shares jumped after reporting first-quarter 2026 results with $1.1 billion in revenue (+19% year over year) and non-GAAP EPS of $6.34. The company also reaffirmed 2026 revenue guidance of $4.25 billion to $4.50 billion and highlighted a Priority Review for zanidatamab with an August 25, 2026 PDUFA date.
Jazz Pharmaceuticals jumps on Q1 revenue surge, EPS beat, and reaffirmed 2026 outlook: Jazz Pharmaceuticals shares jumped after reporting first-quarter 2026 results with $1.1 billion in revenue (+19% year over year) and non-GAAP EPS of $6.34. The company also reaffirmed 2026 revenue guidance of $4.25 billion to $4.50 billion and highlighted a Priority Review for zanidatamab with an August 25, 2026 PDUFA date.
Does Rallies summarize JAZZ news?
Yes. Rallies summarizes JAZZ news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is JAZZ research on Rallies investment advice?
No. Rallies provides research, data, and educational context for JAZZ. It does not provide personalized investment advice.
